Microbot Medical price target raised to $9 from $7 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Microbot Medical (MBOT) to $9 from $7 and keeps a Buy rating on the shares. The firm believes Liberty could outcompete large and expensive capital equipment while reducing radiation exposure as well as physical strain for healthcare providers.